Then, it binds with GLP1 bound to precoated antibody
Retatrutide activates three receptors (GLP-1, GIP, glucagon), tirzepatide activates two (GLP-1, GIP), and semaglutide activates one (GLP-1)
There was a significant decrease in serum concentrations of coagulation factors including PAI-1 and the cell adhesion molecules VCAM-1 and ICAM-1, while there was an increase in IL-13 and IL-8 between T1 and T2 (Extended Data Fig
The most defensible summary is that tirzepatide is the evidence-complete option available today, and retatrutide is the higher-ceiling candidate whose full value and full risk profile will only be known when its phase 3 program is published, scrutinized, and, if warranted, translated into an approval and a label
However, this possibility requires further investigation